CLOPIDOGREL Clinical studies

Objectives Methods Results edit Master subtitle style Click to Conclusion

7/30/12

CONTENT

CIRRHOSIS DOESNT AFFECT THE PHARMACODYNAMICS OF CLOPIDOGREL

Esomeprazole with Clopidogrel Reduces Peptic Ulcer Recurrence

Statins on Clopidogrel Antiplatelet Effectstrial

Clopidogrel and digoxin absence of pharmacodynamic and pharmacokineticinteraction

7/30/12

CIRRHOSIS DOESNT AFFECT THE PHARMACODYNAMICS OF CLOPIDOGREL

Clopidogrel, platelet ADP receptor antagonist used antipletlet agent is converted to an active metabolite via the cytochrome P450 system. parallel-group study of 12 patients with cirrhosis and 12 matched controls. pharmacodynamics were assessed by the inhibition of ADP-induced platelet aggregation and by bleeding time prolongation factor. At Day 10-no a significant difference in mean inhibition of platelet aggregation & bleeding time prolongation factor between groups. No significant adverse events-bleeding events. conclusion-no significant differences in the 7/30/12 pharmacodynamics ofclopidogrelin this group of

Esomeprazole with Clopidogrel Reduces Peptic Ulcer Recurrence

for 2 years, long-term clopidogrel users with histories of peptic ulcers who did not have peptic ulcers at an initial endoscopy examination were assigned randomly to receive the combination of esomeprazole (20 mg/day, before breakfast) and clopidogrel (75 mg/day, at bedtime), or clopidogrel alone for 6 months. A follow-up endoscopy examination was performed at the end of the sixth month and whenever severe symptoms occurred. The cumulative incidence of recurrent peptic ulcer during the 6-month period was 1.2% among patients given the combination of esomeprazole and clopidogrel (n = 83) and 11.0% among patients given clopidogrel alone (n = 82). 7/30/12

Statins on Clopidogrel Antiplatelet Effectstrial

rosuvastatin (Crestor, AstraZeneca) andatorvastatin(Lipitor, Pfizer). 350 post-Percutaneous coronary intervention patients discharged on clopidogrel. In the initial randomization, post-PCI patients were prescribed either rosuvastatin 20 mg or atorvastatin 80 mg, their CYP2C19 status was measured. At 30 days, platelet-function tests were performed & platelet-reactivity index (PRI) was measured. although only 277 remained in the study at the 60day mark. For the statin analysis, there were no differences in 7/30/12effects of rosuvastatin and atorvastatin on the

Clopidogrel and digoxin absence of pharmacodynamic and pharmacokineticinteraction.

12 healthy male subjects assessed who took digoxin 0.25 mg once Click to edit Master subtitle style daily for 20 days withclopidogrel75 mg once daily from day 11 today 20, so as to achieve steady-state conditions with both 7/30/12

Clopidogrelfor cerebrovascular CAPRIE (Clopidogrelversus Aspirin in Patients at prevention. Risk of Ischemic Events)
19,185 patients were recruited. intention-to-treat analysis showed that the relative risk reduction was 8.7% (95% CI 0.3-16.5, p = 0.043) in favor ofclopidogrelfrom an overall annual event rate of ischemic stroke, myocardial infarction, or vascular death, ranging from 5.83% in the aspirin group to 5.33% in theclopidogrelgroup. The percentage of adverse events reported was higher in the aspirin group for all categories except rash, diarrhea, and abnormal liver function. It seems likely thatclopidogrelwill replace ticlopidine for stroke prevention, because of its better safety profile, and comparable 7/30/12 efficacy.Clopidogrelprobably will not replace